HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway

Cancer Research

Volumn 64, Issue 1, 2004, Pages 215-220

  Herrmann, Felix ^a   Lehr, Hans Anton ^a   Drexler, Ingo ^b   Sutter, Gerd ^b   Hengstler, Jan ^a   Wollscheid, Ursula ^a   Seliger, Barbara ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE ANTIGEN; PROTEASOME; PROTEASOME ACTIVATOR 28 ALPHA; PROTEASOME ACTIVATOR 28 BETA; TAPASIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; EMBRYO; FIBROBLAST; GENE AMPLIFICATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE;

3T3 CELLS; ANIMALS; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOTHERAPY; MICE; MICE, KNOCKOUT; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TRANSFECTION;

EID: 1642535582     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-2522-2     Document Type: Article

References (38)

1. Goodenow, R., Vogel, J., and Linsk, R. Histocompatibility antigens on murine tumors. Science (Wash. DC), 230: 777-783, 1985.
2. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18: 89-95, 1997.
3. Ferrone, S., and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16: 487-494, 1995.
4. Mausdley, D. J., and Pond, J. S. Modulation of MHC antigen expression by viruses and oncogenes. Immunol. Today, 12: 429-431, 1991.
5. Seliger, B., Harders, C., Lohmann, S., Momburg, F., Urlinger, S., Tampé, R., and Huber, C. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol., 28: 122-133, 1998.
6. Seliger, B., Harders, C., Wollscheid, U., Staege, M. S., Reske-Kunz, A. B., and Huber, C. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp. Hematol., 24: 1275-1279, 1996.
7. Seliger, B., Maeurer, M. J., and Ferrone, S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21: 455-464, 2000.
8. Seliger, B., Schreiber, K., Delp, K., Meissner, M., Hammers, S., Reichert, T., Pawlischko, K., Tampe, R., and Huber, C., Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens, 57: 39-45, 2001.
9. Qin, Z., Harders, C., Cao, X., Huber, C., Blankenstein, T., and Seliger, B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation I-deficient tumors. Cancer Res., 62: 2856-2860, 2002.
10. Hunter, T. Oncoprotein networks. Cell, 88: 333-346, 1997.
11. Lowy, D. R., and Willumsen, B. M. Function and regulation of Ras. Annu. Rev. Biochem., 62: 851-891, 1993.
12. Paumelle, R., Tulasne, D., Kherrouche, Z., Plaza, S., Leroy, C., Reveneau, S., Vandenbunder, B., Fafeur, V., Tulashe, D., and Reveneau, S. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene, 21: 2309-2319, 2002.
13. Norgaard, P., Law, B., Joseph, H., Page, D. L., Shyr, Y., Mays, D., Pietenpol, J. A., Kohl, N. E., Oliff, A., Coffey, R. J., Jr., Poulsen, H. S., and Moses, H. L., Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGF α/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res., 5: 35-42, 1999.
14. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C., Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig., 99: 1478-1483, 1997.
15. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ulrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC), 230: 1132-1139, 1985.
16. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 5: 953-962, 1990.
17. Slamon, D. J., Godolphin, W., Jones, L. A., Hilt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ulrich, A., and Press, M. F. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
18. Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol., 11: 1936-1942, 1993.
19. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D. J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
20. Murray, J. L., Przepiorka, D., and Ioannides, C. G. Clinical trials of HER-2/neu specific vaccines. Semin. Oncol., 27: 71-75, 2000.
21. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
22. Disis, M., and Cheever, M. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res., 71: 343-371, 1997.
23. Reilly, R. T., Machiels, J. P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D., and Jaffee, E. M. The collaboration of both humoral and cellular HER-2/neu targeted immune responses is required for the complete eradication of HER-2/neu expressing tumors. Cancer Res., 61: 880-883, 2001.
24. Knutson, K. L., Schiffman, K., and Disis, M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J. Clin. Investig., 107: 477-484, 2001.
25. Lollini, P. L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., and Nanni, P. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer, 77: 937-941, 1998.
26. Gossen, M., and Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89: 5547-5551, 1992.
27. Baasner, S., von Melchner, H., Klenner, T., Hilgard, P., and Beckers, T. Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene, 13: 901-911, 1996.
28. Wölfel, T., van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Büschenfelde, K. H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
29. Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T., and Huber, C. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens, 56: 327-336, 2000.
30. Bordier, C. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biochem., 256: 1604-1607, 1981.
31. Neefjes, J. J., Momburg, F., and Hämmerling, G. J. Selective and ATP-dependent translocation of peptides by MHC-encoded transporter. Science (Wash. DC), 261: 769-771, 1993.
32. Wölfel, T., Schneider, J., Meyer Zum Buschenfelde, K. H., Rammensee, H. G., Rotzschke, O., and Falk, K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int. J. Cancer, 57: 413-418, 1994.
33. Drexler, I., Antunes, E., Schmitz, M., Wölfel, T., Huber, C., Erfle, V., Rieber, P., Theobald, M., and Sutter, G. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A* 0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res., 59: 4955-4963, 1999.
34. Meyer, T. H., van Endert, P. M., Uebel, S., Ehring, B., and Tampe, R. Functional expression and purification of the ABC transporter complex associated with antigen processing (TAP) in insect cells. FEBS Lett., 351: 443-447, 1994.
35. van Endert, P. T., Tampé, R., Meyer, T. H., Tisch, R., Bach, J. F., and McDewitt, H. O. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity, 1: 491-500, 1994.
36. Castilleja, A., Ward, N. E., O'Brian, C. A., Swearingen, B., II, Swan, E., Gillogly, M. A., Murray, J. L., Kudelka, A. P., Gershenson, D. M., and Ionannides, C. G. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL: implications for tumor immunogenicity. Mol. Cell. Biochem., 217: 21-33, 2001.
37. Nijman, H. W., van Diest, P. J., Poort-Keesom, K. J., von Mensdorff-Pouilly, S., Vertraeten, R. A., Kummer, A., Meijer, C. J., Melief, C. J., Hilgers, J., and Keenemans, P. T cell infiltration and MHC class I and class II expression in the presence of tumor antigens: an immunohistochemical study in patients with serous epithelial ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol., 94: 114-120, 2001.
38. Lohmann, S., Wollscheid, U., Huber, C., and Seliger, B. Multiple levels of MHC class I downregulation by ras oncogenes. Scand. J. Immunol., 43: 537-544, 1996.